CTOs on the Move

Guardian Pharmacy

www.guardianpharmacy.net

 
Guardian Pharmacy Services, headquartered in Atlanta, Georgia, is the nation’s third largest institutional pharmacy company and one of the fastest growing privately held companies in the state of Georgia. Founded in 2004, Guardian and its partner pharmacies focus on providing exceptional client service and patient care to long-term care customers in assisted living communities, skilled nursing facilities, hospice and behavioral health group homes. Guardian Pharmacy Services` business model allows partner pharmacies to operate as independent local businesses tailoring their services to the needs of customers in their respective markets. We take our responsibility to our customers and their residents very ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Funding

Guardian Pharmacy raised $60M on 07/16/2018

Similar Companies

Pharmaceutical Buyers

Pharmaceutical Buyers is a Cedarhurst, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VoCare

The Vitals 360® measures 6 key vital signs. It´s like having a portable doctor´s office in the home or anywhere. Heart Rate Blood Pressure Blood Oxygen Saturation ECG Heart Rhythms Temperature Glucose (Not available in the...

Hoodia Products

Hoodia Products is a Dublin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Astellas

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms - Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category leader in oncology. At all levels throughout the company our people are committed to the opportunity to positively affect and improve patient lives while remaining socially responsible to our community and those with whom we work and collaborate.

TransCode Therapeutics

TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.